Colony-Stimulating Factors

• 

  Subject Areas on Research

  • 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. 
  • 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. 
  • A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. 
  • A cost analysis of hematopoietic colony-stimulating factors. 
  • A distinct wave of human T cell receptor gamma/delta lymphocytes in the early fetal thymus: evidence for controlled gene rearrangement and cytokine production. 
  • A predictive model for neutropenia associated with cancer chemotherapy. 
  • A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. 
  • Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists. 
  • Balancing the benefits and costs of colony-stimulating factors: a current perspective. 
  • Biosimilars: are they ready for primetime in the United States? 
  • Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. 
  • Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. 
  • Clinical implications for the administration of colony stimulating factors. 
  • Colony stimulating factors for chemotherapy induced febrile neutropenia. 
  • Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. 
  • Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. 
  • Deletion of carboxy-terminal residues of murine granulocyte-macrophage colony-stimulating factor results in a loss of biologic activity and altered glycosylation. 
  • Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. 
  • Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia. 
  • Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. 
  • Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. 
  • Effects of hematopoietic growth factors following myeloablation in a primate model. 
  • Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. 
  • Evidence-based use of colony-stimulating factors in elderly cancer patients. 
  • Expression of human interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines. 
  • Granulocyte colony-stimulating factors: finding the right indication. 
  • Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells. 
  • Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. 
  • Granulocyte-macrophage colony-stimulating factor primes neutrophils by activating a pertussis toxin-sensitive G protein not associated with phosphatidylinositol turnover. 
  • Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. 
  • Hematopoietic growth factors in the older cancer patient. 
  • Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. 
  • High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates. 
  • Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. 
  • Human thymic epithelial cells produce granulocyte and macrophage colony-stimulating factors. 
  • Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. 
  • Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. 
  • Introduction. Neutropenia risk models in oncology. 
  • Macrophages Contribute to the Spermatogonial Niche in the Adult Testis. 
  • Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. 
  • Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. 
  • Myeloid growth factors clinical practice guidelines in oncology. 
  • Myeloid growth factors. 
  • Myeloid growth factors. 
  • Myeloid growth factors. Clinical practice guidelines in oncology. 
  • Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. 
  • Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. 
  • Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. 
  • Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. 
  • Recombinant human granulocyte-macrophage colony-stimulating factor produces fever. 
  • Reculturing of cells from primary CFU-C colonies. 
  • Renal epithelial cell-derived monocyte colony stimulating factor as a local informant of renal injury and means of monocyte activation. 
  • Risk assessment in oncology clinical practice. From risk factors to risk models. 
  • Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. 
  • Risks and consequences of chemotherapy-induced neutropenia. 
  • Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy. 
  • Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. 
  • Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. 
  • Supportive care of the marrow transplant recipient: the Seattle Experience. 
  • The colony-stimulating factors: use to prevent and treat neutropenia and its complications. 
  • The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. 
  • The myeloid growth factors. 
  • The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. 
  • Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. 
  • Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how? 
  • Two different types of granulocyte colony-stimulating factor produced by bovine lung tissue. 
  • Tyrosine phosphorylation in human neutrophil. 
  • Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. 
  • Update of the economic analyses of the use of the colony-stimulating factors. 
  • Use of re-randomized data in meta-analysis. 
• 

  Keywords of People

  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases